Phase Ⅱ clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma
10.3760/cma.j.issn.0366-6999.2011.19.008
- Author:
Chi YIHEBALI
1
;
Jian-Hong REN
;
Lin YANG
;
Cheng-Xu CUI
;
Jun-Ling LI
;
Jin-Wan WANG
Author Information
1. Department of Medical Oncology, Cancer Hospital & Institute,Chinese Academy of Medical Sciences, Beijing 100021, China
- Keywords:
gastric cancer;
modified DCF regimen;
docetaxel;
cis-platinum;
5-fluorouracil
- From:
Chinese Medical Journal
2011;125(19):2997-3002
- CountryChina
- Language:Chinese
-
Abstract:
Background A phase Ⅲ trial involving docetaxel, cisplatin, and fluorouracil (DCF) in the treatment of advanced gastric cancer was shown to have superior efficacy compared to cisplatin and fluorouracil alone, but with a high rate of hematologic toxicity. To reduce toxicity while maintaining the efficacy of DCF, we reduced the doses of docetaxel (D) and cis-platinum (CDDP), and administered 5-fluorouracil (5-FU) via a continuous intravenous (CIV) infusion.Methods Chemotherapy-naive patients with gastric adenocarcinomas received D (60 mg/m2 1 hour on day 1), CDDP (30 mg/m2on days 1 and 2), and 5-FU (1500 mg·m-2·24 h-1 CIV on days 1 and 8 every 3 weeks). The primary endpoint was the response rate.Results Fourteen patients were enrolled. Based on the efficacy evaluation following at least 2 cycles of treatment, there was 7.1％ complete remission (CR), 71％ partial remission (PR), 14％ stable disease (NC/SD), and 7.1％ progressive disease (PD). The median survival time was 13 months. Nine patients (64％) had grade Ⅲ-Ⅳ neutropenia, and 4 patients (29％) had grade Ⅳ neutropenia, among whom 1 had grade Ⅳ neutropenia with grade Ⅲ nausea and vomiting.Conclusion The modified DCF regimen is highly active and has a favorable toxicity profile in Chinese patients with gastric cancer.
